Oral BG-12 (dimethyl fumarate) for relapsing―remitting multiple sclerosis: a review of DEFINE and CONFIRMHAVRDOVA, Eva; HUTCHINSON, Michael; KURUKULASURIYA, Nuwan C et al.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 15, pp 2145-2156, issn 1465-6566, 12 p.Article

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple SclerosisGOLD, Ralf; KAPPOS, Ludwig; DAWSON, Katherine T et al.The New England journal of medicine. 2012, Vol 367, Num 12, pp 1098-1107, issn 0028-4793, 10 p.Article

Evaluation of the Safety of Rituximab in Combination With a Tumor Necrosis Factor Inhibitor and Methotrexate in Patients With Active Rheumatoid Arthritis: Results From a Randomized Controlled TrialGREENWALD, Maria W; SHERGY, William J; KAINE, Jeffrey L et al.Arthritis and rheumatism. 2011, Vol 63, Num 3, pp 622-632, issn 0004-3591, 11 p.Article

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple SclerosisFOX, Robert J; MILLER, David H; VIGLIETTA, Vissia et al.The New England journal of medicine. 2012, Vol 367, Num 12, pp 1087-1097, issn 0028-4793, 11 p.Article

An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapyGOFFE, Bernard; PAPP, Kim; GRATTON, David et al.Clinical therapeutics. 2005, Vol 27, Num 12, pp 1912-1921, issn 0149-2918, 10 p.Article